Pain News and Research

Latest Pain News and Research

Positive results from Creabilis CT327 Phase IIa study in atopic dermatitis

Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, announced positive results in the Phase IIa study of its lead product CT327 in atopic dermatitis.

15 Dec 2010

NCI initiates crolibulin/cisplatin combination Phase II trial in anaplastic thyroid cancer

EpiCept Corporation today announced that the National Cancer Institute (NCI) has initiated a Phase II trial with crolibulinTM (EPC2407). The trial will assess the drug's efficacy and safety in combination with cisplatin in patients with anaplastic thyroid cancer (ATC). CrolibulinTM is a vascular disruption and apoptosis inducing agent that has demonstrated potent anti-tumor activity in both preclinical and early clinical studies.

15 Dec 2010

Anxious and depressed patients more likely to report worse results after hip replacement

Patients who suffer from anxiety and depression are more likely to report worse results after a hip replacement. A year-long wait for the operation also entails significant costs to both society and the individual, reveals a new thesis from the University of Gothenburg, Sweden.

15 Dec 2010

DARA's KRN5500 reduces allodynia in Phase 2a study for neuropathic pain in cancer patients

DARA BioSciences, Inc. announced today additional positive results from its successfully completed KRN5500 Phase 2a Clinical Study for treatment of neuropathic pain in patients with cancer. Statistically significant primary endpoint results were released earlier.

15 Dec 2010

Watson files generic Exalgo ANDA, confirms patent challenge from Mallinckrodt

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. – Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Hydromorphone Hydrochloride Extended-release Tablets, 8 mg, 12 mg, and 16 mg.

14 Dec 2010

World's first remote 3D keyhole surgery to be performed at University of Surrey

Doctors will shortly be performing the world's first remote 3D keyhole surgery during a symposium at the University of Surrey. Keyhole surgery - where doctors operate on organs through a tiny incision - reduces the length of hospital stays and post-operative complications. This also means that patients experience less scarring and pain. 3D keyhole surgery is a state-of-the-art extension of standard keyhole surgery that uses 3D cameras like those used to make the film 'Avatar'. It puts the surgeon right inside the patient's body and significantly improves accuracy.

14 Dec 2010

Clinical trial investigates pomalidomide in only U.S. study for multiple myeloma

Multiple myeloma, a type of blood cancer in which malignant plasma cells are overproduced in the bone marrow, has led to an estimated 20,000 new diagnoses and 11,000 deaths in 2010. Patients with the disease, who have already failed previous treatments, may be considered for a currently enrolling Phase II study, examining a unique drug combination.

14 Dec 2010

FDA accepts for filing Pacira's EXPAREL NDA for postsurgical pain management

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, announced today that the New Drug Application (NDA) for EXPAREL™, a long-acting bupivacaine for postsurgical pain management, has been accepted for filing by the U.S. Food and Drug Administration (FDA).

14 Dec 2010

Rheumatologists raise awareness on early diagnosis and treatment of inflammatory arthritis

In people who develop symptoms of inflammatory arthritis, early diagnosis and treatment can have a significant impact on the course of disease—in some cases even preventing deformity and loss of function from rheumatoid arthritis, according to an article in the December issue of JCR: Journal of Clinical Rheumatology.

14 Dec 2010

Preliminary results from Phase 1b/2a trial of MediciNova's ibudilast in opioid addicts announced

Drug addiction investigators with joint appointments at Columbia University Medical Center and the New York State Psychiatric Institute along with MediciNova Inc, a biopharmaceutical company publicly traded on the Nasdaq Global Market and the Jasdaq Market of the Osaka Securities Exchange, today reported preliminary results of the company's neurological drug candidate, ibudilast (MN-166/AV411), in a Phase 1b/2a trial in opioid addicts. The study was largely funded by the National Institute on Drug Abuse (NIDA) with MediciNova supplementation.

14 Dec 2010

GTx announces Capesaris proof of concept clinical trail in men with advanced prostate cancer

BETHESDA, Md.,GTx, Inc. this weekend presented results of the Capesaris™ (GTx-758) proof of concept pharmacokinetic-pharmacodynamic (PK/PD) clinical trial at the Annual Meeting of the Society of Urologic Oncology.

14 Dec 2010

National Institutes of Health honors Nevada nursing professor with $377,000 for ischemia study

University of Nevada, Reno Orvis School of Nursing researcher Michele Pelter has been awarded $377,000 from the National Institutes of Health to study detection of ischemia, a condition that can lead to heart attacks.

14 Dec 2010

Top-line results from Inhibitex's FV-100 Phase II clinical trial for treatment of shingles

Inhibitex, Inc. today reported top-line safety and efficacy data from its Phase II clinical trial of FV-100, an oral antiviral compound being developed to treat herpes zoster, more commonly referred to as shingles. The study was the first clinical trial to assess the antiviral activity of FV-100, included 350 shingles patients and compared two once-daily doses of FV-100 (200 mg and 400 mg) to an active control, valacyclovir, one of the most commonly-used antiviral drugs to treat shingles.

14 Dec 2010

Consumers, employers and insurers work to incorporate reform's new rules

Big employers and insurers continue to brace for health reform's changes and new rules. In other news, CalPERS gives the new health law positive early reviews while other reports focus on how reform could impact Medicare coverage.

13 Dec 2010

Pain Therapeutics completes special, one-time nondividend cash distribution

Pain Therapeutics, Inc. announced today the completion of a special, one-time nondividend cash distribution of $2.00 per share, or an aggregate of about $86 million. In connection with this event, Nasdaq® will adjust the price of PTIE by $2.00 per share at today's open.

13 Dec 2010

iTech Medical receives Health Canada approval for Muscle Pattern Recognition System

iTech Medical, Inc., a medical information technology company, announced today that it has received Health Canada approval for the Company's Muscle Pattern Recognition (MPR) System, a non-invasive clinical assessment tool being developed to assist in the diagnosis and treatment of back and neck pain, one of the most common chronic conditions in Canada.

13 Dec 2010

Ascension Orthopedics reports first implantation of PyroTITAN Humeral Resurfacing Implant in France

Ascension Orthopedics, Inc., a market leader in PyroCarbon orthopedic implants, announces the first implantation of the PyroTITAN™ Humeral Resurfacing Implant in France. The PyroTITAN was implanted in a 68-year-old patient suffering from painful primary arthritis with synovial osteochondromotosis at Imperial Park Clinic in Nice – making it a surgical first in continental Europe. The patient was discharged from the hospital the next day and reported good pain relief 10 days after surgery.

13 Dec 2010

First Edition: December 13, 2010

Today's health policy headlines highlight today's expected ruling by a Virginia federal court judge on the health law's constitutionality.

13 Dec 2010

Lubricants associated with higher rating of sexual pleasure

A recent survey by researchers at Indiana University has found that women who used lubricants during sex, reported significantly higher levels of satisfaction and pleasure.

13 Dec 2010

Infinity extends global strategic alliance with Mundipharma for development, commercialization of IPI-926

Infinity Pharmaceuticals, Inc. today announced the extension of its global strategic alliance with Mundipharma International Corporation Limited to develop and commercialize IPI-926, Infinity's novel Smoothened antagonist, as well as development candidates arising from Infinity's phosphoinositol-3-kinase (PI3K) and discovery programs.

13 Dec 2010

Pain News and Research

Latest Pain News and Research

Positive results from Creabilis CT327 Phase IIa study in atopic dermatitis

NCI initiates crolibulin/cisplatin combination Phase II trial in anaplastic thyroid cancer

Anxious and depressed patients more likely to report worse results after hip replacement

DARA's KRN5500 reduces allodynia in Phase 2a study for neuropathic pain in cancer patients

Watson files generic Exalgo ANDA, confirms patent challenge from Mallinckrodt

World's first remote 3D keyhole surgery to be performed at University of Surrey

Clinical trial investigates pomalidomide in only U.S. study for multiple myeloma

FDA accepts for filing Pacira's EXPAREL NDA for postsurgical pain management

Rheumatologists raise awareness on early diagnosis and treatment of inflammatory arthritis

Preliminary results from Phase 1b/2a trial of MediciNova's ibudilast in opioid addicts announced

GTx announces Capesaris proof of concept clinical trail in men with advanced prostate cancer

National Institutes of Health honors Nevada nursing professor with $377,000 for ischemia study

Top-line results from Inhibitex's FV-100 Phase II clinical trial for treatment of shingles

Consumers, employers and insurers work to incorporate reform's new rules

Pain Therapeutics completes special, one-time nondividend cash distribution

iTech Medical receives Health Canada approval for Muscle Pattern Recognition System

Ascension Orthopedics reports first implantation of PyroTITAN Humeral Resurfacing Implant in France

First Edition: December 13, 2010

Lubricants associated with higher rating of sexual pleasure

Infinity extends global strategic alliance with Mundipharma for development, commercialization of IPI-926

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Pain News and Research

Latest Pain News and Research

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in